Mostrar el registro sencillo del ítem

dc.contributor.authorAldámiz-Echevarria, Teresa
dc.contributor.authorResino, Salvador 
dc.contributor.authorBellón, José M
dc.contributor.authorJimenez-Sousa, Maria Angeles 
dc.contributor.authorMiralles, Pilar
dc.contributor.authorMedrano, Luz Maria 
dc.contributor.authorCarrero, Ana
dc.contributor.authorDíez, Cristina
dc.contributor.authorPérez-Latorre, Leire
dc.contributor.authorFanciulli, Chiara
dc.contributor.authorGarcia-Broncano, Pilar 
dc.contributor.authorBerenguer, Juan
dc.date.accessioned2019-11-04T09:47:55Z
dc.date.available2019-11-04T09:47:55Z
dc.date.issued2019-07-26
dc.identifier.citationJ Transl Med. 2019 Jul 26;17(1):244es_ES
dc.identifier.issn1479-5876es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/8546
dc.description.abstractBACKGROUND: Mitochondrial DNA (mtDNA) haplogroups have been associated with advanced liver fibrosis and cirrhosis in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Our aim was to determine whether mtDNA haplogroups are associated with liver-related events (LREs) in HIV/HCV-coinfected patients. METHODS: We carried out a retrospective cohort study in HIV/HCV-coinfected patients who were potential candidates for therapy with interferon and ribavirin (IFN/Rib) between 2000 and 2009. The primary endpoint was the occurrence of LREs (decompensation or hepatocellular carcinoma). mtDNA genotyping was performed using the Sequenom MassARRAY platform. We used Fine and Gray proportional hazards model to test the association between mtDNA haplogroups and LREs, considering death as a competitive risk. RESULTS: The study population comprised 243 patients, of whom 40 had advanced fibrosis or cirrhosis. After a median follow-up of 7.7 years, 90 patients treated with IFN/Rib achieved sustained viral response (SVR), 18 patients had LREs, and 11 patients died. Patients with haplogroup H had lower cumulative incidence than patients with other haplogroups (p = 0.012). However, patients with haplogroup T had higher cumulative incidence than patients with other haplogroups (p = 0.074). In the multivariate analysis, haplogroup T was associated with an increased hazard of developing LREs [adjusted subhazard ratio (aSHR) = 3.56 (95% CI 1.13;11.30); p = 0.030]; whereas haplogroup H was not associated with lower hazard of LREs [aSHR = 0.36 (95% CI 0.10;1.25); p = 0.105]. When we excluded patients who achieved SVR during follow-up, we obtained similar SHR values. CONCLUSIONS: European mitochondrial haplogroups may influence the natural history of chronic hepatitis C.es_ES
dc.description.sponsorshipThis study was supported by grants from Fondo de Investigación de Sanidad en España (Spanish Funds for Health Research [FIS]), grant numbers PI14/01094 and PI17/00657 to JB, PI14CIII/00011 and PI17CIII/00003 to SR. The study was also funded by the RD16CIII/0002/0002 and RD16/0025/0017 projects as part of the Plan Nacional R + D + I and cofunded by ISCIII- Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER). JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS), Refs INT15/00079 and INT16/00100. LMM, MAJS, and PGB are supported by “Instituto de Salud Carlos III” (grant numbers CD14/00002, CD13/00013, CP14/0010, and FI12/00036; respectively).es_ES
dc.language.isoenges_ES
dc.publisherBioMed Central (BMC) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectChronic hepatitis Ces_ES
dc.subjectCirrhosises_ES
dc.subjectHIVes_ES
dc.subjectLiver-related outcomeses_ES
dc.subjectMitochondriaes_ES
dc.subjectmtDNA haplogroupses_ES
dc.titleEuropean mitochondrial haplogroups predict liver-related outcomes in patients coinfected with HIV and HCV: a retrospective studyes_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID31349790es_ES
dc.format.volume17es_ES
dc.format.number1es_ES
dc.format.page244es_ES
dc.identifier.doi10.1186/s12967-019-1997-xes_ES
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1479-5876es_ES
dc.relation.publisherversionhttps://doi.org/10.1186/s12967-019-1997-xes_ES
dc.identifier.journalJournal of translational medicinees_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI14/01094es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI17/00657es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI14CIII/00011es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI17CIII/00003es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD16CIII/0002/0002es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD16/0025/0017es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/INT15/00079es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/INT16/00100es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CD14/00002es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CD13/00013es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CP14/0010es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/FI12/00036es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional